ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,306.04
      0.02%
      US Tech 100
      18,387.60
      0.38%
      Dow Jones
      38,852.86
      -0.55%
      Brent Oil
      84.245
      -0.09%
      Bitcoin
      68,389.56
      0.14%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Carisma Therapeutics Inc (CARM)

      7. Carisma Therapeutics Inc (CARM) News

      CARM

      Carisma Therapeutics (CARM)

      Carisma Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CARM
      DateTimeSourceHeadlineSymbolCompany
      05/28/20247:39PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CARMCarisma Therapeutics Inc
      05/16/20247:30AMPR Newswire (US)Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-MonocyteNASDAQ:CARMCarisma Therapeutics Inc
      05/09/20247:52AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CARMCarisma Therapeutics Inc
      05/09/20247:41AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
      05/09/20247:30AMPR Newswire (US)Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CARMCarisma Therapeutics Inc
      05/08/202411:45AMBusiness WireCarmila: Withdrawal of funds for the liquidity contractNASDAQ:CARMCarisma Therapeutics Inc
      05/08/202411:45AMBusiness WireCarmila: Réduction des moyens du contrat de liquiditéNASDAQ:CARMCarisma Therapeutics Inc
      05/08/20247:30AMPR Newswire (US)Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024NASDAQ:CARMCarisma Therapeutics Inc
      05/07/202411:45AMBusiness WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
      05/07/202411:45AMBusiness WireCARMILA: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
      05/06/20247:30AMPR Newswire (US)Carisma Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceNASDAQ:CARMCarisma Therapeutics Inc
      05/02/20247:30AMPR Newswire (US)Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical OfficerNASDAQ:CARMCarisma Therapeutics Inc
      04/24/20245:05PMPR Newswire (US)Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingNASDAQ:CARMCarisma Therapeutics Inc
      04/24/202412:43PMBusiness WireCarmila: Launch of a Share Buyback Program for €10 MillionNASDAQ:CARMCarisma Therapeutics Inc
      04/24/202412:43PMBusiness WireCarmila : Lancement d’un programme de rachat d’actions pour 10 millions d’eurosNASDAQ:CARMCarisma Therapeutics Inc
      04/22/20244:35PMPR Newswire (US)Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingNASDAQ:CARMCarisma Therapeutics Inc
      04/17/202411:45AMBusiness WireCarmila : Information financière au 31 mars 2024NASDAQ:CARMCarisma Therapeutics Inc
      04/17/202411:45AMBusiness WireCarmila: First-quarter 2024 Financial InformationNASDAQ:CARMCarisma Therapeutics Inc
      04/05/202411:45AMBusiness WireCarmila: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and Article 223-16 of the Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
      04/05/202411:45AMBusiness WireCarmila : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
      04/03/20247:00AMPR Newswire (US)Carisma Therapeutics to Present at Upcoming ConferencesNASDAQ:CARMCarisma Therapeutics Inc
      04/01/20248:35AMPR Newswire (US)Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CARMCarisma Therapeutics Inc
      04/01/20247:00AMPR Newswire (US)Carisma Therapeutics Announces Changes to its Board of DirectorsNASDAQ:CARMCarisma Therapeutics Inc
      03/21/20245:00PMPR Newswire (US)Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual MeetingNASDAQ:CARMCarisma Therapeutics Inc
      03/15/202412:45PMBusiness WireCARMILA : INFORMATION RELATIVE A LA REMUNERATION DES DIRIGEANTS MANDATAIRES SOCIAUXNASDAQ:CARMCarisma Therapeutics Inc
      03/15/202412:45PMBusiness WireCarmila: Information Relating to Executive Corporate Officer CompensationNASDAQ:CARMCarisma Therapeutics Inc
      03/15/202412:45PMBusiness WireCarmila : Communiqué de mise à disposition du Document d’enregistrement universel 2023NASDAQ:CARMCarisma Therapeutics Inc
      03/15/202412:45PMBusiness WireCarmila: Filing of the 2023 Universal Registration DocumentNASDAQ:CARMCarisma Therapeutics Inc
      03/08/202411:45AMBusiness WireCORRIGE ET REMPLACE : Carmila : Evolution de la composition du Conseil d’administration suite au Conseil d’administration du 7 mars 2024NASDAQ:CARMCarisma Therapeutics Inc
      03/08/202411:45AMBusiness WireCORRECTING and REPLACING: Carmila: Changes in the composition of the Board of Directors following the meeting of the Board of Directors on 7 March 2024NASDAQ:CARMCarisma Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:CARM